We are live on ! Find out more
STLN

Starling Oncology Institute, Inc. Common Stock
STLN

53 hedge funds and large institutions have $206M invested in Starling Oncology Institute, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

6% more funds holding

Funds holding: 50 → 53 (+3)

19.86% less ownership

Funds ownership: 113.76% → 93.89% (-20%)

21% less capital invested

Capital invested by funds: $261M → $206M (-$54.9M)

64% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 14

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
53
Holders Change
+3
Holders Change %
+6%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
5
Reduced
14
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$7.21M
2
WAM
Weiss Asset Management
Massachusetts
+$6.28M
3
Bank of America
Bank of America
North Carolina
+$4.65M
4
DKCM
Davidson Kempner Capital Management
New York
+$2.37M
5
PMAM
Picton Mahoney Asset Management
Ontario, Canada
+$1.51M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$55M
2
ECM
Element Capital Management
New York
-$5.97M
3
SRCM
Sage Rock Capital Management
New York
-$4.71M
4
KC
Kepos Capital
New York
-$2.96M
5
GCL
Glazer Capital LLC
New York
-$1.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Beryl Capital Management
California
$1.97M – – –
CCA
27
Castle Creek Arbitrage
Colorado
$1.62M – – –
PMAM
28
Picton Mahoney Asset Management
Ontario, Canada
$1.49M +$1.51M +150,000 New
TCM
29
Tenor Capital Management
New York
$1.4M +$506K +50,287 +56%
SFM
30
Sphera Funds Management
Israel
$1.26M -$365K -36,268 -22%
FTCM
31
First Trust Capital Management
Illinois
$1.24M +$560K +55,606 +81%
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$1.24M +$1.25M +124,360 New
SRCM
33
Sage Rock Capital Management
New York
$1.05M -$4.71M -468,109 -82%
DAM
34
Deltec Asset Management
New York
$995K – – –
SCM
35
Saba Capital Management
New York
$951K +$963K +95,685 New
FIG
36
Fortress Investment Group
New York
$857K +$866K +86,056 New
PC
37
Periscope Capital
Ontario, Canada
$744K -$254K -25,200 -25%
OPU
38
Omni Partners US
California
$688K +$696K +69,099 New
AC
39
Aristeia Capital
Connecticut
$622K +$629K +62,500 New
QGA
40
Q Global Advisors
Texas
$498K – – –
DCM
41
Dupont Capital Management
Delaware
$497K – – –
PSAMP
42
P. Schoenfeld Asset Management (PSAM)
New York
$471K -$23.2K -2,300 -5%
Baird Financial Group
43
Baird Financial Group
Wisconsin
$458K – – –
Nomura Holdings
44
Nomura Holdings
Japan
$333K +$337K +33,500 New
WRBC
45
W.R. Berkley Corp
Connecticut
$247K – – –
Morgan Stanley
46
Morgan Stanley
New York
$200K -$50.2K -4,984 -20%
AA
47
AQR Arbitrage
Connecticut
$174K – – –
Goldman Sachs
48
Goldman Sachs
New York
$167K +$169K +16,772 New
CAPTRUST Financial Advisors
49
CAPTRUST Financial Advisors
North Carolina
$157K -$7.72K -767 -5%
EAM
50
Exos Asset Management
New York
$50K – – –
1
2
3

STLN Hedge Fund Activity: Q2 2021 in Review

53 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Institute, Inc. Common Stock (STLN) for Q2 2021, worth a combined $206M — down 21% from $261M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new STLN positions and 8 closed out — a net gain of 4 holders — while 5 added to existing stakes and 14 trimmed.

The largest buyer was 683 Capital Management, opening a new position worth an estimated $7.21M. The largest seller was Deerfield Management, cutting an estimated $55M.

  • 53 institutional investors held Starling Oncology Institute, Inc. Common Stock (STLN) as of Q2 2021, up from 50 in Q1 2021.
  • Funds reported $206M of Starling Oncology Institute, Inc. Common Stock stock for Q2 2021, down 21% quarter-over-quarter.
  • 12 funds opened new Starling Oncology Institute, Inc. Common Stock positions in Q2 2021 and 8 closed out, a net change of +4 holders.
  • The largest Starling Oncology Institute, Inc. Common Stock buyer in Q2 2021 was 683 Capital Management, an estimated $7.21M added.
  • The largest Starling Oncology Institute, Inc. Common Stock seller in Q2 2021 was Deerfield Management, an estimated $55M sold.

Based on aggregated 13F filings for Q2 2021.